Secukinumab for severe Takayasu arteritis
Treatments studied
Part of Heart & circulation, Skin clinical trials.
This trial tests a drug called secukinumab to see if it can help people with severe Takayasu arteritis, a rare disease that causes inflammation in the blood vessels. The drug works by blocking a protein that drives inflammation, which may reduce disease activity and help people lower their steroid dose.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 15 years or older.
- You have been diagnosed with Takayasu arteritis.
- Your disease is active and severe, meaning it has not responded well to usual treatments or has caused serious problems like stroke, heart issues, or kidney problems.
- You are able to take prednisone (a steroid) at a dose between 10 and 50 mg per day at the start of the study.
- You are not pregnant or breastfeeding, and you agree to use effective birth control during the study and for 6 months after treatment.
- You do not have active infections, cancer, or certain other medical conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies treatment options for people age 14 and older with severe, active Takayasu arteritis causing major circulation problems and organ strain. It may help reduce inflammation and complications when the disease is flaring and difficult to control.
This trial compares a personalized treatment plan based on your specific disease markers to standard care, aiming to find which is more effective and safer for active Takayasu's arteritis. It may help researchers learn how to better control inflammation and prevent flares.
This trial tests whether adding pirfenidone (a drug that reduces scarring) to your usual treatment helps limit blood vessel thickening and scarring in Takayasu arteritis. You must still have some signs of active disease despite being on standard therapy.
This trial compares two medicines—tofacitinib and methotrexate—to see which works better for controlling active Takayasu’s arteritis. It also looks at safety in people with this condition who need treatment right now.
This study looks at whether it is safe for people with Takayasu arteritis to stop taking their biologic medication (like TNF inhibitors or tocilizumab) if they have been in remission—meaning their disease has been quiet—for a long time. You might join this trial if your condition has been stable for years and you haven't needed steroids lately.
This UK-based study uses a questionnaire to learn about how people with Takayasu arteritis (a rare type of vasculitis) are treated and what they think about their care. If you have TAK, your answers can help doctors understand how to better manage this condition.
Hear when a new Takayasu Arteritis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.